Ionis Pharmaceuticals, Inc.
Modulators of PCSK9 expression
Last updated:
Abstract:
The present embodiments provide methods, compounds, and compositions useful for inhibiting PCSK9 expression, which may be useful for treating, preventing, or ameliorating a disease associated with PCSK9.
Status:
Grant
Type:
Utility
Filling date:
23 Mar 2018
Issue date:
31 Dec 2019